Enforcement · June 2026
The FDA sent 25 warning letters to GLP-1 telehealth firms
In the week of 15 June 2026 the FDA issued 25 warning letters to telehealth companies over allegedly false or misleading promotional claims about compounded GLP-1 products. This is the enforcement wave to understand, because the conduct it targets is marketing language that appears on a great many websites.
What was actually cited
The letters concern promotional claims — how compounded products were described and advertised — rather than the act of compounding itself. That distinction matters: a company can be operating a lawful 503A arrangement and still receive a letter for describing the product in a way the agency considers false or misleading.
The claims that get companies in trouble
Four patterns recur. Describing a compounded product as though it were FDA approved, or as a generic of an approved medicine — it is neither. Presenting efficacy figures from trials of the approved product as though they applied to the compounded one. Omitting risk information that the approved labelling carries. And presenting a starting-dose or promotional price as a standing rate.
That last one is a pricing practice as much as a safety one, and it is the reason this site refuses to rank a program that publishes no maintenance-dose price.
How to read a program's marketing after this
The phrase "FDA-approved compounded" is always false; no compounded product is FDA approved. A site quoting "up to 20% weight loss" for a compounded product is borrowing a number from a trial of a different, reviewed medicine. And a price described as "from $X" with no maintenance figure behind it is the pattern the agency's letters describe.
Our provider records print the evidence status of every figure and mark programs that publish no maintenance price as unrankable for exactly this reason.
What it signals
Enforcement attention is on the telehealth layer, not only the pharmacies. Earlier FDA activity in this market specifically cited companies that never disclose the compounding pharmacy's identity — and 29 of the 37 programs in our database still do not name theirs. That is the disclosure gap most likely to attract attention next, and the one a buyer can check today.
Verified . Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Questions
Did the FDA take action against GLP-1 telehealth companies?
Yes. In the week of 15 June 2026 the FDA issued 25 warning letters to telehealth companies over allegedly false or misleading promotional claims about compounded GLP-1 products.
What marketing claims are not allowed for compounded GLP-1s?
Describing a compounded product as FDA approved or as a generic; applying efficacy results from trials of the approved product to a compounded one; omitting risk information carried in the approved labelling; and presenting a starting-dose or promotional price as a standing rate.
Is 'FDA-approved compounded semaglutide' a real thing?
No. That phrase is always false. The FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed.